Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC 50 of 5.8 nM. It also acts as an efficient inducer of hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptors. Furthermore, Pitavastatin exhibits a range of therapeutic activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC 50 of 5.8 nM. It also acts as an efficient inducer of hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptors. Furthermore, Pitavastatin exhibits a range of therapeutic activities, including anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects. |
In vitro | Pitavastatin inhibits the growth of a panel of ovarian cancer cells, including those considered most likely to represent HGSOC, grown as a monolayers (IC 50 =0.4-5 μM) or as spheroids (IC50 = 0.6-4 μM) [4]. Pitavastatin (1 μM; 48 hours ) induces apoptosis, evidenced by the increased activity of executioner caspases-3,7 and caspase-8 and caspase-9 in Ovcar-8 cells and Ovcar-3 cells [4]. Pitavastatin (1 μM, 48 hours) resulted in PARP cleavage in Ovcar-8 cells [4]. Western Blot Analysis [1] Cell Line: Ovcar-8 cells Concentration: 1 μM Incubation Time: 48 hours Result: Induced PARP cleavage. |
In vivo | Pitavastatin (59 mg/kg; p.o.; twice daily for 28 days) resulted in significant tumour regression [4]. Animal Model: 4 week old female NCR Nu/Nu female mice (bearing Ovcar-4 tumours) [4] Dosage: 59 mg/kg Administration: p.o.; twice daily for 28 days Result: Caused significant tumour regression. |
分子量 | 421.46 |
分子式 | C25H24FNO4 |
CAS No. | 147511-69-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pitavastatin 147511-69-1 Compound T7072 Inhibitor inhibitor inhibit